Embrace the power of real-world evidence.

NWEH stands for NorthWest EHealth, we are a UK based company that are working to redefine clinical trial delivery through technology platforms utilising real-world data. 

NWEH provides end-to-end clinical research services for sponsors across but not limited to, trial feasibility assessments, trial or study design, patient and public involvement and engagement (PPIE), clinical research delivery, participant registries, real-world evidence generation, SDTM and OMOP data set generation and advanced data analysis.   

Using its proprietary FARSITE platform, NWEH can search over 20 million de-identified UK electronic health records to confirm patient population size and protocol viability in minutes.  Its ConneXon platform provides secure Electronic Data Capture and real-world data integration throughout the trial, safety reporting during the trial and exports submission-ready datasets for regulatory submissions.  

NWEH was the first organisation globally to conduct large-scale pre-licence trials using routinely collected electronic healthcare data to provide evidence of safety and improved outcomes for a real-world population. Today, NWEH uses two proprietary platforms to harness real-world data throughout the entire clinical trial lifecycle.  

FARSITE is a proven find-and-recruit solution that eliminates traditional barriers to trial start-up, while ConneXon is a secure validated, real-world data-enabled Electronic Data Capture (EDC) designed to streamline clinical trial management.  

NWEH’s ConneXon platform is a data-first clinical research platform that securely integrates real-world data from consented participants directly from source systems and automatically transforms it into analysis-ready, CDISC SDTM-compliant datasets. Where study-specific data collection is required, ConneXon provides an optional, fully integrated EDC, enabling sponsors to capture only the data that cannot be sourced electronically. 

NWEH has deep expertise across a range of therapeutic areas, with a particularly strong track record in respiratory disease, cardiovascular health, diabetes and metabolic conditions, and lipid disorders. 

The landmark Salford Lung Studies with GSK was the world’s first large-scale pre-licence real-world randomised clinical trial, which has become the benchmark for the use of real-world data in clinical evaluation. 

More recently, NWEH supported Novartis on the VICTORION-SPIRIT study, using its digital platforms to find, recruit, and monitor participants in a primary care setting as part of a pioneering cholesterol-lowering treatment study. In the area of diabetes and metabolic conditions, NWEH is collaborating with Eli Lilly, further demonstrating its capability to deliver complex real-world studies at scale in primary care. 

NWEH also has an active focus on women’s health research and continues to expand its capabilities across new disease areas.  

The NWEH expert team helps trial sponsors create effective study strategies, optimising study design, streamlining participant identification, and accelerating trial delivery, utilising market leading technology platforms.  

The process typically begins with a feasibility assessment using the FARSITE platform to rapidly identify eligible patient populations from anonymised, otherwise known as pseudonymised electronic health records without the need for costly, time-consuming site set-up.  

From there, NWEH’s team of clinical, data, and technology experts work alongside sponsors at every stage for end-to-end study delivery including protocol design, site mobilisation, participant recruitment, electronic data capture, real-time safety monitoring, and data analysis, harnessing the ConneXon platform capabilities.   

For over 15 years, NWEH has been driven by its mission to revolutionise clinical trials. Founded in 2008 and based in Manchester, NWEH provides software and services to the clinical trials market, allowing pharmaceutical companies and contract research organisations to conduct feasibility studies, recruit patients, and run clinical trials and research. Over that time, NWEH has grown from a pioneering NHS and academic collaboration into an internationally recognised clinical trial technology provider. 

NWEH works with a broad range of organisations across the life sciences and healthcare ecosystem. Its solutions streamline the entire trial process, from feasibility assessments and optimised trial design to participant recruitment, real-world trial delivery, real-time safety monitoring, and advanced data analytics empowering sponsors across the pharmaceutical industry.  

Partners have included major pharmaceutical companies such as GSK, Novartis and Eli Lilly, NHS trusts and GP networks, academic institutions including the University of Manchester, and regulatory bodies such as the MHRA through its CPRD data service.  

NWEH partnerships have also included the Northern Care Alliance NHS Foundation Trust, Salford CCG, and the University of Manchester reflecting NWEH’s unique position at the intersection of industry, the NHS, and academia.  

Real-world data (RWD) is health information collected outside of traditional, controlled clinical trial settings. It includes data generated through everyday patient interactions with the healthcare system such as electronic health records (EHRs) from GP practices, hospital records, pharmacy data, wearable devices and patient-reported outcomes.  

Unlike data from tightly controlled randomised controlled trials (RCTs), real-world data reflects how patients live and respond to treatments in their normal environment, without oversight. When analysed, this data generates real-world evidence (RWE) clinical insights that can support drug development, regulatory submissions, and healthcare decision-making.